It has to be noted here that the metabolic alterations supported by KRAS mutations depend on the tissue context, for example KRAS-driven lung cancer displayed increased BCAA metabolism, being the opposite in PDAC [66]. This evidence concerns the gene ARID4B and lung carcinoma.